Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.

[1]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[2]  Anil K. Jain,et al.  Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. , 2008, Journal of the American College of Cardiology.

[3]  S. Humphries,et al.  Role of β adrenergic receptor polymorphisms in heart failure: Systematic review and meta‐analysis , 2008, European journal of heart failure.

[4]  S. Liggett,et al.  Genetic Variation Within the β1-Adrenergic Receptor Gene Results in Haplotype-Specific Expression Phenotypes , 2008, Journal of cardiovascular pharmacology.

[5]  Julie A. Johnson,et al.  Pharmacogenetics of β‐Blockers , 2007 .

[6]  Harlan M Krumholz,et al.  Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. , 2007, JAMA.

[7]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[8]  I. Zineh,et al.  Relation of β2-Adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients With Heart Failure , 2007 .

[9]  Deborah A Meyers,et al.  Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. , 2006, American journal of respiratory and critical care medicine.

[10]  D. Marchuk,et al.  Redefining heart failure: the utility of genomics. , 2006, Journal of the American College of Cardiology.

[11]  L. Lazzeroni,et al.  A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure , 2006 .

[12]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[13]  P. Amouyel,et al.  The impact of beta‐adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure * , 2005, European journal of heart failure.

[14]  D. Feldman,et al.  Mechanisms of Disease: β-adrenergic receptors—alterations in signal transduction and pharmacogenomics in heart failure , 2005, Nature Clinical Practice Cardiovascular Medicine.

[15]  Julie A. Johnson,et al.  Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. , 2005, Pharmacogenetics and genomics.

[16]  Jonathan Seidman,et al.  Genetic causes of human heart failure. , 2005, The Journal of clinical investigation.

[17]  P. Amouyel,et al.  Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure , 2005, Pharmacogenetics and genomics.

[18]  K. Adams,et al.  β‐adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure , 2005, Clinical pharmacology and therapeutics.

[19]  S. Liggett,et al.  Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Liggett,et al.  Pharmacology and physiology of human adrenergic receptor polymorphisms. , 2003, Annual review of pharmacology and toxicology.

[21]  G. Dorn,et al.  β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.

[22]  S. Ball,et al.  An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study , 2003, European journal of heart failure.

[23]  G. Jennings,et al.  Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. , 2003, Pharmacogenetics.

[24]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[25]  S. Liggett.  Pharmacogenetics of Beta-1- and Beta-2-Adrenergic Receptors , 2000, Pharmacology.

[26]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[27]  D. A. Mason,et al.  A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.

[28]  D. Rubin,et al.  Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .

[29]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[30]  I. Zineh,et al.  Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. , 2007, The American journal of cardiology.

[31]  L. Lazzeroni,et al.  A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. , 2006, Proceedings of the National Academy of Sciences of the United States of America.